Agree with Dr. @Muayad Almahariq, however, if planning to treat these synchronously, I would favor two setups, one for lung and one for HN. I would want to keep doses in lung tight to minimize toxicity as much as possible. Having to fight with arms and butterfly arcs is going to make that much tough...

Admittedly, this is an outside-the-box answer, but if the patient has a good performance status, consider treatment with carbo/taxol and concurrent RT to both cancers at the same time. Carbo/taxol is category 1 recommendation for lung ca ChemoRT. It is not first line for HNC ChemoRT, but acceptable ...

I agree with the considerations noted in the answers above, including individualized assessments of performance status and optimization of supportive care and patient setup. I would add that the terms "locally advanced H+N cancer" and "locally advanced NSCLC" can describe cancers that are quite...

First, assess the performance status of the patient to determine whether they can receive multimodal curative-intent therapy. If so, then assay both tumors for actionable mutations and if they exist, proceed with induction systemic therapy for the site that will likely most respond. At the same tim...

This is a good case to consider Proton Beam Therapy to minimize the bath of low-intermediate dose to large volumes of normal tissue. 

I've had this situation once, but to make matters worse, he had multifocal H&N primaries (soft palate and larynx), but thankfully no cervical nodes. His lung cancer was much more advanced (T4N2 if I remember correctly) so we started with definitive CRT to his lung lesions and I was pleasantly su...